Abstract
A sizable fraction of healthy blood donors have cross-reactive T cells to SARS-CoV-2 peptides due to prior infection with seasonal coronavirus. Understanding the role of cross-reactive T cells in immunity to SARS-CoV-2 has implications for managing the COVID-19 pandemic. We show that individuals with documented history of seasonal coronavirus have a similar SARS-CoV-2 infection rate and COVID-19 severity as those with no prior history of seasonal coronavirus. Our findings suggest prior infection with seasonal coronavirus does not provide immunity to subsequent infection with SARS-CoV-2.
Introduction
Early in the COVID-19 pandemic, immunologists discovered that 20% to 50% of people never exposed to SARS-CoV-2 possessed "cross-reactive" memory T cells capable of recognizing parts of the virus. These cells were likely generated during previous infections with seasonal coronaviruses—the common cold varieties such as OC43, HKU1, 229E, and NL63. A critical public health question emerged: does this pre-existing immunity provide clinical protection? If these T cells offered a head start to the immune system, they might explain the wide variation in COVID-19 severity. This study investigates whether a documented history of seasonal coronavirus infection correlates with lower infection rates or milder disease outcomes.
Methods and Datasets
This retrospective cohort study utilized Electronic Health Records (EHR) from two major academic medical centers: Stanford Health Care (2.9 million patients) and the University of Washington (5.4 million patients). From this pool of over 8 million people, researchers identified 2,768 individuals who met specific inclusion criteria:
- Pre-Pandemic Phase: Received an RT-PCR test for seasonal coronaviruses between January 1, 2016, and February 1, 2020.
- Pandemic Phase: Received an RT-PCR test for SARS-CoV-2 after February 1, 2020.
By comparing patients with a positive seasonal coronavirus history against those with a negative history, the team isolated the impact of prior infection. COVID-19 severity was categorized as "Mild" (not hospitalized) or "Moderate/Severe" (hospitalized or intubated).
Results
The study found that a history of seasonal coronavirus infection does not provide clinical protection against SARS-CoV-2.
Infection Rates
Among the 302 patients with a history of seasonal coronavirus, 3.3% eventually tested positive for SARS-CoV-2. In comparison, 3.1% of the 2,466 patients with no such history tested positive. This difference was statistically insignificant ($P = 0.77$ for the combined cohort).
Disease Severity
For patients who did contract COVID-19, the severity of the disease was comparable regardless of prior seasonal infection history. In the combined cohort, 40.0% of those with a prior seasonal infection had moderate-to-severe cases, compared to 48.1% in the control group ($P = 0.63$).
Discussion
The most significant takeaway is the decoupling of cellular biology from clinical outcomes. While cross-reactive T cells are known to exist, this study suggests they do not effectively prevent or mitigate COVID-19. This lack of protection was consistent across geographic regions and age groups; notably, older patients (≥65), who typically have more lifetime exposure to seasonal viruses, saw no added benefit.
Limitations and Future Directions
The study's primary limitation is the small number of SARS-CoV-2 positive individuals within the prior-infection group ($n=10$), which limits the statistical power of the severity analysis. Furthermore, the reliance on RT-PCR records may introduce testing bias, as many seasonal infections go undocumented. The authors suggest that prospective studies measuring actual T cell levels before SARS-CoV-2 exposure are necessary to definitively determine if specific types of cross-reactive T cells might offer subtle benefits not detectable in this EHR-based analysis.
Summary updated